214 related articles for article (PubMed ID: 10399622)
1. The functional anatomy of noradrenergic neurons in Parkinson's disease.
Soldani P; Fornai F
Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
[No Abstract] [Full Text] [Related]
2. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
3. Nondopaminergic neurons in Parkinson's disease.
Hirsch EC; Orieux G; Muriel MP; Francois C; Feger J
Adv Neurol; 2003; 91():29-37. PubMed ID: 12449099
[No Abstract] [Full Text] [Related]
4. Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons.
Insua D; Suárez ML; Santamarina G; Sarasa M; Pesini P
Neurobiol Aging; 2010 Apr; 31(4):625-35. PubMed ID: 18573571
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter.
Hartmann A; Hunot S; Hirsch EC
Exp Neurol; 2003 Dec; 184(2):561-4. PubMed ID: 14769349
[No Abstract] [Full Text] [Related]
6. The role of the locus coeruleus in the development of Parkinson's disease.
Gesi M; Soldani P; Giorgi FS; Santinami A; Bonaccorsi I; Fornai F
Neurosci Biobehav Rev; 2000 Aug; 24(6):655-68. PubMed ID: 10940440
[TBL] [Abstract][Full Text] [Related]
7. The locus ceruleus norepinephrine system: functional organization and potential clinical significance.
Benarroch EE
Neurology; 2009 Nov; 73(20):1699-704. PubMed ID: 19917994
[No Abstract] [Full Text] [Related]
8. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?
Kish SJ
Adv Neurol; 2003; 91():39-49. PubMed ID: 12442662
[No Abstract] [Full Text] [Related]
9. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
10. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
11. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Fulceri F; Biagioni F; Ferrucci M; Lazzeri G; Bartalucci A; Galli V; Ruggieri S; Paparelli A; Fornai F
Brain Res; 2007 Mar; 1135(1):219-29. PubMed ID: 17222394
[TBL] [Abstract][Full Text] [Related]
12. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
[No Abstract] [Full Text] [Related]
13. Mechanism of cell death in experimental models of Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Funct Neurol; 2000; 15(4):229-37. PubMed ID: 11213526
[No Abstract] [Full Text] [Related]
14. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
15. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
16. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
17. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
18. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease.
Baloyannis SJ; Costa V; Baloyannis IS
J Neurol Sci; 2006 Oct; 248(1-2):35-41. PubMed ID: 16753180
[TBL] [Abstract][Full Text] [Related]
19. Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology.
Singh S
Int J Neurosci; 2020 Mar; 130(3):251-261. PubMed ID: 31575316
[TBL] [Abstract][Full Text] [Related]
20. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
